skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

asco_podcast

 

May 26, 2017


The 53rd annual meeting of the American Society of Clinical Oncology (ASCO) will be held in Chicago from June 2-6, 2017. This audio-only podcast features Informa Pharma Intelligence analysts Dr. Robert Jeng (Biomedtracker), Dr. David Dahan (Biomedtracker), Dr. Dominique Fontanilla (Datamonitor Healthcare), and Dr. Maria Berezina (Citeline) as they discuss notable abstracts which were released on Wednesday, May 17, 2017. Podcast topics include:

 

  • IDO inhibitors epacadostat and RG6078

 

  • PD-1 inhibitor Keytruda in gastric cancer

 

  • CAR-T therapies bb2121 and CTL119

 

  • Breast cancer including Perjeta and PARP inhibitors

 

 

Listen to the podcast here today

Read also

  • Biomedtracker: see the drug development process through anal...

    39th Annual J.P. Morgan Healthcare Conference 2021

    Keep up with events as they unfold at the 39th Annual J.P. Morgan Annual Healthcare Conference on January 11-14, 2021. Pharma Intelligence and Insights journalists will bring you real time reporting, highlighting important events and key takeaways from every day of the largest and most informative healthcare investment symposium in the industry.

  • Datamonitor Healthcare: data analysis and insight, Biomedtra...

    Gene therapy manufacturers

    Given the transformative nature of regenerative medicines, which can yield greatly improved patient responses, meet unmet need, and now exist as viable products on the market, cell and gene therapeutics developers over the past several years have been drawing deal attention, not only through collaborative partnerships, but also as acquisition targets.

  • Biomedtracker: see the drug development process through anal...

    Deconstructing the KRAS+ market opportunity

    By Daniel Chancellor

    With arguably the standout data from the 2019 American Society for Clinical Oncology (ASCO) annual meeting, Amgen has become the first company to show that KRAS, beyond its role as an oncogene, is also a viable drug target

    Topics BioPharmaceutical Drug Review

;

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: